SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001104659-23-088600
Filing Date
2023-08-08
Accepted
2023-08-08 07:25:31
Documents
14
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A tm2323052d2_10qa.htm   iXBRL 10-Q/A 38141
2 EXHIBIT 31.1 tm2323052d2_ex31-1.htm EX-31.1 9668
3 EXHIBIT 31.2 tm2323052d2_ex31-2.htm EX-31.2 9578
  Complete submission text file 0001104659-23-088600.txt   255031

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA trda-20230331.xsd EX-101.SCH 3018
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE trda-20230331_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trda-20230331_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2323052d2_10qa_htm.xml XML 4803
Mailing Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210
Business Address ONE DESIGN CENTER PLACE SUITE 17-500 BOSTON MA 02210 857-305-1825
Entrada Therapeutics, Inc. (Filer) CIK: 0001689375 (see all company filings)

IRS No.: 813983399 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-40969 | Film No.: 231149326
SIC: 2834 Pharmaceutical Preparations